View Item 

Show simple item record

Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients

dc.contributor.authorPapaleontiou, Maria
dc.contributor.authorHawley, Sarah T.
dc.contributor.authorHaymart, Megan R.
dc.date.accessioned2017-12-15T16:47:30Z
dc.date.available2017-12-15T16:47:30Z
dc.date.issued2016-02
dc.identifier.citationPapaleontiou, Maria; Hawley, Sarah T.; Haymart, Megan R. (2016). "Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients." The Oncologist 21(2): 165-171.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139948
dc.publisherWiley Periodicals, Inc.
dc.publisherAlphaMed Press
dc.subject.otherThyroid neoplasms
dc.subject.otherRisk
dc.subject.otherBone density
dc.subject.otherThyrotropin
dc.titleEffect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
dc.contributor.affiliationumDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
dc.contributor.affiliationumDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139948/1/onco0165.pdf
dc.identifier.doi10.1634/theoncologist.2015-0179
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceI Sugitani, Y Fujimoto. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: A prospective controlled study. Surgery. 2011; 150: 1250 – 1257.
dc.identifier.citedreferenceE Jódar, M Begoña López, L García. Bone changes in pre‐ and postmenopausal women with thyroid cancer on levothyroxine therapy: Evolution of axial and appendicular bone mass. Osteoporos Int. 1998; 8: 311 – 316.
dc.identifier.citedreferenceI Karner, Z Hrgović, S Sijanović. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res. 2005; 10: 480 – 488.
dc.identifier.citedreferenceC Marcocci, F Golia, G Bruno‐Bossio. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab. 1994; 78: 818 – 823.
dc.identifier.citedreferenceCG Müller, TA Bayley, JE Harrison. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid. 1995; 5: 81 – 87.
dc.identifier.citedreferenceTL Paul, J Kerrigan, AM Kelly. Long‐term l ‐thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA. 1988; 259: 3137 – 3141.
dc.identifier.citedreferenceG Pioli, M Pedrazzoni, E Palummeri. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol (Copenh). 1992; 126: 238 – 242.
dc.identifier.citedreferenceDS Ross, RM Neer, EC Ridgway. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary‐thyroid axis with l ‐thyroxine. Am J Med. 1987; 82: 1167 – 1170.
dc.identifier.citedreferenceS Tournis, JD Antoniou, CG Liakou. Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin Endocrinol (Oxf). 2015; 82: 197 – 204.
dc.identifier.citedreferenceLY Wang, AW Smith, FL Palmer. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low‐ and intermediate‐risk patients with differentiated thyroid carcinoma. Thyroid. 2015; 25: 300 – 307.
dc.identifier.citedreferenceC‐Y Guo, AP Weetman, R Eastell. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf). 1997; 46: 301 – 307.
dc.identifier.citedreferenceF Hawkins, D Rigopoulou, K Papapietro. Spinal bone mass after long‐term treatment with l ‐thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tissue Int. 1994; 54: 16 – 19.
dc.identifier.citedreferenceAWC Kung, T Lorentz, SCF Tam. Thyroxine suppressive therapy decreases bone mineral density in post‐menopausal women. Clin Endocrinol (Oxf). 1993; 39: 535 – 540.
dc.identifier.citedreferenceTG De Melo, da LV Assumpção, AO Santos. Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma. Thyroid Res. 2015; 8: 7.
dc.identifier.citedreferenceJL Reverter, E Colomé, S Holgado. Bone mineral density and bone fracture in male patients receiving long‐term suppressive levothyroxine treatment for differentiated thyroid carcinoma. Endocrine. 2010; 37: 467 – 472.
dc.identifier.citedreferenceC Marcocci, F Golia, E Vignali. Skeletal integrity in men chronically treated with suppressive doses of l ‐thyroxine. J Bone Miner Res. 1997; 12: 72 – 77.
dc.identifier.citedreferenceB Biondi, DS Cooper. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010; 20: 135 – 146.
dc.identifier.citedreferenceInternational Osteoporosis Foundation. Osteoporosis in men: Why change needs to happen. Available at: http://share.iofbonehealth.org/WOD/2014/thematic‐report/WOD14‐Report.pdf. Accessed April 1, 2015.
dc.identifier.citedreferenceL Gennari, JP Bilezikian. Osteoporosis in men. Endocrinol Metab Clin North Am. 2007; 36: 399 – 419.
dc.identifier.citedreferenceSE Roberts, MJ Goldacre. Time trends and demography of mortality after fractured neck of femur in an English population, 1968‐98: Database study. BMJ. 2003; 327: 771 – 775.
dc.identifier.citedreferenceMJ Goldacre, SE Roberts, D Yeates. Mortality after admission to hospital with fractured neck of femur: Database study. BMJ. 2002; 325: 868 – 869.
dc.identifier.citedreferenceMJ Parker, JK Anand. What is the true mortality of hip fractures?. Public Health. 1991; 105: 443 – 446.
dc.identifier.citedreferenceJA Cauley, DE Thompson, KC Ensrud. Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11: 556 – 561.
dc.identifier.citedreferenceSurveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Thyroid Cancer. Available at http://seer.cancer.gov/statfacts/html/thyro.html. Accessed April 1, 2015.
dc.identifier.citedreferenceHaugen BR, Alexander EK, Bible KC et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2015 [Epub ahead of print]
dc.identifier.citedreferenceB Biondi, S Filetti, M Schlumberger. Thyroid‐hormone therapy and thyroid cancer: A reassessment. Nat Clin Pract Endocrinol Metab. 2005; 1: 32 – 40.
dc.identifier.citedreferenceP Roger, M Taton, J Van Sande. Mitogenic effects of thyrotropin and adenosine 3′,5′‐monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988; 66: 1158 – 1165.
dc.identifier.citedreferenceR Baliram, L Sun, J Cao. Hyperthyroid‐associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest. 2012; 122: 3737 – 3741.
dc.identifier.citedreferenceE Abe, RC Marians, W Yu. TSH is a negative regulator of skeletal remodeling. Cell. 2003; 115: 151 – 162.
dc.identifier.citedreferenceSH Downs, N Black. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non‐randomised studies of health care interventions. J Epidemiol Community Health. 1998; 52: 377 – 384.
dc.identifier.citedreferenceJA Franklyn, J Betteridge, J Daykin. Long‐term thyroxine treatment and bone mineral density. Lancet. 1992; 340: 9 – 13.
dc.identifier.citedreferenceG Görres, A Kaim, A Otte. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. Eur J Nucl Med. 1996; 23: 690 – 692.
dc.identifier.citedreferenceAC Heijckmann, MSP Huijberts, P Geusens. Hip bone mineral density, bone turnover and risk of fracture in patients on long‐term suppressive l ‐thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol. 2005; 153: 23 – 29.
dc.identifier.citedreferenceJ Lehmke, U Bogner, D Felsenberg. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: A risk of early osteopaenia in post‐menopausal women. Clin Endocrinol (Oxf). 1992; 36: 511 – 517.
dc.identifier.citedreferenceJJ Stĕpán, Z Límanová. Biochemical assessment of bone loss in patients on long‐term thyroid hormone treatment. Bone Miner. 1992; 17: 377 – 388.
dc.identifier.citedreferenceJ Toivonen, R Tähtelä, K Laitinen. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol. 1998; 138: 667 – 673.
dc.identifier.citedreferenceCH Chen, JF Chen, BY Yang. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc. 2004; 103: 442 – 447.
dc.identifier.citedreferenceT Diamond, L Nery, I Hales. A therapeutic dilemma: Suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 1991; 72: 1184 – 1188.
dc.identifier.citedreferenceS Giannini, M Nobile, L Sartori. Bone density and mineral metabolism in thyroidectomized patients treated with long‐term l ‐thyroxine. Clin Sci (Lond). 1994; 87: 593 – 597.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0165.pdf
Size:
985.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.